



AbTherx and Spice Biotechnologies have launched a multi-program antibody discovery collaboration utilizing the Atlas™ mouse platform

(Collaboration, ADC, Phase 3)



AstraZeneca's Triexo Aerosphere has received UK approval with a near-zero GWP propellant, achieving a 99.9% reduction in global warming impact for respiratory inhalers

(UK, Approval, Sustainability)



The FDA has approved Roche's VENTANA MET assay, paving the way for the precise selection of NSCLC patients for AbbVie's EMRELIS

(FDA, Approval, NSQ-NSCLC)



According to APHINITY data, Roche's Perjeta-based regimen demonstrated a 17% reduction in the risk of death for individuals with HER2-positive early-stage breast cancer after ten years

(Clinical trial, Breast cancer, Oncology)



Septerna partnered with Novo Nordisk to develop oral small molecule therapies targeting obesity and other cardiometabolic conditions

(Collaboration, Small molecule therapy, Obesity, Cardiometabolic)



AbbVie and ADARx partner on next-gen siRNA therapies with a licensing option, combining their expertise to advance treatments in neuroscience, immunology and oncology

(Collaboration, Neuroscience, Immunology and Oncology)



Incyte's Zynyz® has received FDA approval as a first-line treatment for advanced anal cancer, showing significant survival benefits with its PD-1 inhibitor

(FDA, Oncology)



Amneal's BREKIYA injection has been approved by the FDA for acute migraine and cluster headaches, becoming the first ready-to-use DHE autoinjector for patient self-administration; it is expected to be available for patients in H2 2025

(FDA, approval)



Skye Bioscience partners with Arecor Therapeutics to develop an enhanced formulation of nimacimab for obesity, leveraging proprietary technology to potentially improve the candidate's properties

(Collaboration, Obesity)